Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2023 Results published in the Media Release
08 Nov 2023 According to an Eli Lilly and Company media release, based on results from this study, company received the U. S. FDA approval to Zepbound injection.
26 Jun 2023 Results (Between March 29, 2021, and April 10, 2023) assessing the efficacy and safety of tirzepatide versus placebo, for weight management in people living with obesity and type 2 diabetes, published in the Lancet.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com